



Resource impact template

Resource impact

Published: 2 November 2023

Last updated: 4 October 2023

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for active psoriatic arthritis:

- [Bimekizumab for treating active psoriatic arthritis](#) (2023) NICE technology appraisal guidance 916
- [Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2022) NICE technology appraisal guidance 815
- [Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2022) NICE technology appraisal guidance 803
- [Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2022) NICE technology appraisal guidance 768
- [Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2018) NICE technology appraisal guidance 543
- [Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2018) NICE technology appraisal guidance 537
- [Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs](#) (2017) NICE technology appraisal guidance 445
- [Apremilast for treating active psoriatic arthritis](#) (2017) NICE technology appraisal guidance 433
- [Ustekinumab for treating active psoriatic arthritis](#) (2015) NICE technology appraisal guidance 340
- [Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis](#) (2010) NICE technology appraisal guidance 199